Marker Therapeutics Inc (MRKR)

[erg61]

Does anyone have thoughts about the article that was written on April 17, 2019 by Max Chatsko?

Here are a couple of excerpts:

“Marker therapeutics list eight different clinical programs for its MultiTAA T cell platform, and another six programs using different approaches.
That can be viewed in a number of ways. Perhaps it harbors a lot of potential, or suggest the company has a lack of focus. Either way, taking 14 clinical programs in to mid and late stage trials will be awfully expensive, especially for a company valued at just 250 million that ended 2018 with only 62 million in cash and cash equivalents. Any delay in reporting data which could send the stock higher or give Wall Street something to cling to just reduces an already minuscule margin of error.”
“ Marker therapeutics needs to deliver a win from its bulging pipeline soon to justify its immuno oncology approach. This isn’t the news Wall Street wants to read.”

Thoughts anyone!
If this has been addressed, I’m sorry, I must have missed it.

Thanks in advance!